The following is a summary of "Association of eosinophil-to-monocyte ratio with asthma exacerbations in adults: a ...

Q1 2025 Earnings Conference Call April 29, 2025 6:45 AM ETCompany ParticipantsAndy Barnett - Head of IRPascal Soriot ...

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD: Paris Wednesday, April 16, 2025, 10:00 Hrs [IST] Sanofi shared new pro ...

Drilling down into subgroups of patients, Sanofi also claimed that amlitelimab demonstrated “compelling efficacy” in patients ...

New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthma Lunsekimig now targeting ... in a patient sub-group defined by biomarkers (eosinophils ≥300 cells/ml and ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria ...

GSK's severe asthma therapy Nucala could find a new ... METREX involved patients with a range of eosinophil levels and showed a statistically significant improvement for Nucala versus placebo ...

PARIS, France and TARRYTOWN, NY, USA I April 18, 2025 I The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of ...